% 0期刊文章% Sumita捻股机%一个山姆Payabvash %安森王% Sreeja Kodali %一个Tijil Agarwal Andrew Silverman % % Christoph Stretz %一个宾宾郑林% Gloria洛佩兹Cardenas %劳伦sans %一个查尔斯Matouk约瑟夫·辛德勒% %一个凯文Sheth瑞安·赫伯特% %一个尼尔斯·彼得森圣地亚哥奥尔特加古铁雷斯% % T可怜的担保物和恶性CT灌注概要文件与脆弱性增加有关血管内治疗期间血压降低2019% (S57.002) % D J神经病学% P S57.002 % V 92% N % X 15补充目的:检查之间的关系侧枝循环不佳,对降低血压(BP)在血管内治疗(EVT)。首页背景:大的卡车阻塞(LVO)后,血液流向灌注缺血半影很大程度上取决于抵押品。Intraprocedural BP与梗塞相关增长和减少不利的功能结果。我们假设贫困患者侧枝循环利用CT灌注和CTA成像评估的风险增加,梗塞发展与intraprocedural BP减少有关。设计/方法:我们前瞻性的111 LVO中风患者接受了EVT在两个综合中风中心。188金宝慱官网下载卷的动脉组织延迟> 10秒(ATD10)估计快速软件;根据先前的研究,恶性灌注概要文件被定义为ADT10 > 100毫升。络脉独立得分在CTA图像使用Miteff和rLMC系统。英国石油公司减少被定义为入学intraprocedural最低英国石油公司和英国石油公司之间的区别;收缩压(SBP)和降低平均动脉压(MAP)测量。梗塞发展被定义为不同随访MRI梗死体积和RAPID-assessed CBF < 30%核心梗塞体积。结果:七十九例患者(平均年龄69±14,47个f,意味着署16)人成功将近(TICI 2 b / 3)包括在分析中。基线地图是106±19毫米汞柱; median MAP reduction was 21 (IQR 5–37). Malignant perfusion profile (n=21) was an independent predictor of infarct progression after adjusting for age, sex, admission NIHSS, and time to EVT (mean 40 vs. 22 ml, p=0.019). A significant interaction was found between SBP reduction and both malignant profile (p=0.01) and collateral status (p=0.03, Miteff; p=0.07, rLMC). For every 10 mmHg MAP reduction, patients with poor versus excellent collaterals experienced an average infarct growth of 7 ml versus 1 ml, respectively.Conclusions: Patients with malignant perfusion profiles and poor collaterals are at significantly higher risk of infarct progression related to intraprocedural BP reduction.Disclosure: Dr. Strander has nothing to disclose. Dr. Payabvash has nothing to disclose. Dr. Wang has nothing to disclose. Dr. Kodali has nothing to disclose. Dr. Silverman has nothing to disclose. Dr. Agarwal has nothing to disclose. Dr. Stretz has nothing to disclose. Dr. Zheng-Lin has nothing to disclose. Dr. Lopez Cardenas has nothing to disclose. Dr. Sansing has nothing to disclose. Dr. Schindler has nothing to disclose. Dr. Matouk has nothing to disclose. Dr. Hebert has nothing to disclose. Dr. Sheth has received royalty, license fees, or contractual rights payments from Alva Health. Dr. Sheth has received research support from Biogen, Novartis, Bard, and Hyperfine. Dr. Ortega Gutierrez has nothing to disclose. Dr. Petersen has nothing to disclose. %U